Sign in or Register   Sign in or Register
  |  

Mouse Anti-BRD4 (AA 530-580) Recombinant Antibody (CBYY-0806) (CBMAB-0809-YY)

This product is mouse antibody that recognizes BRD4. The antibody CBYY-0806 can be used for immunoassay techniques such as: WB, IHC, IHC-P
See all BRD4 antibodies

Summary

Host Animal
Mouse
Specificity
Human
Clone
CBYY-0806
Antibody Isotype
IgG1
Application
WB, IHC, IHC-P

Basic Information

Immunogen
This antibody was developed against a recombinant protein corresponding to amino acids: PQPAKPQQVIQHHHSPRHHKSDPYSTGHLREAPSPLMIHSPQMouseQFQSLTHQSPPQQNVQPKKQELRAASVVQPQPLVVVKEEKIHSPIIRSEPFSPSLRPEPPKHPESIKAPVHLPQRPEMKPVDVGRPVIRPPEQNAPPP
Specificity
Human
Antibody Isotype
IgG1
Clonality
Monoclonal
Application Notes
The COA includes recommended starting dilutions, optimal dilutions should be determined by the end user.

Formulations & Storage [For reference only, actual COA shall prevail!]

Format
Liquid
Storage
Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.
Epitope
AA 530-580

Target

Full Name
bromodomain containing 4
Introduction
The protein encoded by this gene is homologous to the murine protein MCAP, which associates with chromosomes during mitosis, and to the human RING3 protein, a serine/threonine kinase. Each of these proteins contains two bromodomains, a conserved sequence motif which may be involved in chromatin targeting. This gene has been implicated as the chromosome 19 target of translocation t(15;19)(q13;p13.1), which defines an upper respiratory tract carcinoma in young people. Two alternatively spliced transcript variants have been described.
Entrez Gene ID
UniProt ID
Alternative Names
Bromodomain Containing 4; Chromosome-Associated Protein; HUNK1; Bromodomain-Containing Protein 4; Bromodomain-Containing 4; Protein HUNK1; HUNKI; MCAP; CAP;
Function
Chromatin reader protein that recognizes and binds acetylated histones and plays a key role in transmission of epigenetic memory across cell divisions and transcription regulation. Remains associated with acetylated chromatin throughout the entire cell cycle and provides epigenetic memory for postmitotic G1 gene transcription by preserving acetylated chromatin status and maintaining high-order chromatin structure (PubMed:23589332, PubMed:23317504, PubMed:22334664).
During interphase, plays a key role in regulating the transcription of signal-inducible genes by associating with the P-TEFb complex and recruiting it to promoters. Also recruits P-TEFb complex to distal enhancers, so called anti-pause enhancers in collaboration with JMJD6. BRD4 and JMJD6 are required to form the transcriptionally active P-TEFb complex by displacing negative regulators such as HEXIM1 and 7SKsnRNA complex from P-TEFb, thereby transforming it into an active form that can then phosphorylate the C-terminal domain (CTD) of RNA polymerase II (PubMed:23589332, PubMed:19596240, PubMed:16109377, PubMed:16109376, PubMed:24360279).
Promotes phosphorylation of 'Ser-2' of the C-terminal domain (CTD) of RNA polymerase II (PubMed:23086925).
According to a report, directly acts as an atypical protein kinase and mediates phosphorylation of 'Ser-2' of the C-terminal domain (CTD) of RNA polymerase II; these data however need additional evidences in vivo (PubMed:22509028).
In addition to acetylated histones, also recognizes and binds acetylated RELA, leading to further recruitment of the P-TEFb complex and subsequent activation of NF-kappa-B (PubMed:19103749).
Also acts as a regulator of p53/TP53-mediated transcription: following phosphorylation by CK2, recruited to p53/TP53 specific target promoters (PubMed:23317504).
Isoform B: Acts as a chromatin insulator in the DNA damage response pathway. Inhibits DNA damage response signaling by recruiting the condensin-2 complex to acetylated histones, leading to chromatin structure remodeling, insulating the region from DNA damage response by limiting spreading of histone H2AX/H2A.x phosphorylation.
Biological Process
Cellular response to DNA damage stimulus Source: UniProtKB
Chromatin organization Source: UniProtKB-KW
Chromatin remodeling Source: UniProtKB
Negative regulation by host of viral transcription Source: FlyBase
Negative regulation of DNA damage checkpoint Source: UniProtKB
Positive regulation of G2/M transition of mitotic cell cycle Source: MGI
Positive regulation of histone H3-K36 trimethylation Source: UniProtKB
Positive regulation of I-kappaB kinase/NF-kappaB signaling Source: UniProtKB
Positive regulation of transcription, DNA-templated Source: UniProtKB
Positive regulation of transcription by RNA polymerase II Source: UniProtKB
Positive regulation of transcription elongation from RNA polymerase II promoter Source: UniProtKB
Regulation of inflammatory response Source: UniProtKB
Regulation of phosphorylation of RNA polymerase II C-terminal domain Source: UniProtKB
Regulation of transcription involved in G1/S transition of mitotic cell cycle Source: MGI
Viral process Source: UniProtKB-KW
Cellular Location
Nucleus; Chromosome. Associates with acetylated chromatin (PubMed:21890894, PubMed:16109376). Released from chromatin upon deacetylation of histones that can be triggered by different signals such as activation of the JNK pathway or nocodazole treatment (PubMed:21890894, PubMed:16109376). Preferentially localizes to mitotic chromosomes, while it does not localizes to meiotic chromosomes (PubMed:21890894, PubMed:16109376).
Isoform B: Chromosome
Involvement in disease
A chromosomal aberration involving BRD4 is found in a rare, aggressive, and lethal carcinoma arising in midline organs of young people. Translocation t(15;19)(q14;p13) with NUTM1 which produces a BRD4-NUTM1 fusion protein.
PTM
Phosphorylation by CK2 disrupt the intramolecular binding between the bromo domain 2 and the NPS region and promotes binding between the NPS and the BID regions, leading to activate the protein and promote binding to acetylated histones. In absence of phosphorylation, BRD4 does not localize to p53/TP53 target gene promoters, phosphorylation promoting recruitment to p53/TP53 target promoters.

Wang, S., Shen, D., Zhao, L., Yuan, X., Cheng, J., Yu, B., ... & Liu, H. (2020). Discovery of [1, 2, 4] triazolo [1, 5-a] pyrimidine derivatives as new bromodomain-containing protein 4 (BRD4) inhibitors. Chinese Chemical Letters, 31(2), 418-422.

Kim, S. Y., Zhang, X., Schiattarella, G. G., Altamirano, F., Ramos, T. A., French, K. M., ... & Hill, J. A. (2020). Epigenetic reader BRD4 (bromodomain-containing protein 4) governs nucleus-encoded mitochondrial transcriptome to regulate cardiac function. Circulation, 142(24), 2356-2370.

Liang, D., Yu, Y., & Ma, Z. (2020). Novel strategies targeting bromodomain-containing protein 4 (BRD4) for cancer drug discovery. European Journal of Medicinal Chemistry, 200, 112426.

Padmanabhan, A., Alexanian, M., Linares-Saldana, R., González-Terán, B., Andreoletti, G., Huang, Y., ... & Srivastava, D. (2020). BRD4 (bromodomain-containing protein 4) interacts with GATA4 (GATA binding protein 4) to govern mitochondrial homeostasis in adult cardiomyocytes. Circulation, 142(24), 2338-2355.

Brasier, A. R., & Zhou, J. (2020). Validation of the epigenetic reader bromodomain-containing protein 4 (BRD4) as a therapeutic target for treatment of airway remodeling. Drug discovery today, 25(1), 126-132.

Otto, C., Schmidt, S., Kastner, C., Denk, S., Kettler, J., Müller, N., ... & Wiegering, A. (2019). Targeting bromodomain-containing protein 4 (BRD4) inhibits MYC expression in colorectal cancer cells. Neoplasia, 21(11), 1110-1120.

Zhou, Z., Li, X., Liu, Z., Huang, L., Yao, Y., Li, L., ... & Zhang, Q. Q. (2020). A bromodomain-containing protein 4 (BRD4) inhibitor suppresses angiogenesis by regulating AP-1 expression. Frontiers in pharmacology, 11, 1043.

Tian, B., Liu, Z., Yang, J., Sun, H., Zhao, Y., Wakamiya, M., ... & Brasier, A. R. (2018). Selective antagonists of the bronchiolar epithelial NF-κB-bromodomain-containing protein 4 pathway in viral-induced airway inflammation. Cell reports, 23(4), 1138-1151.

Ouyang, L., Zhang, L., Liu, J., Fu, L., Yao, D., Zhao, Y., ... & Liu, B. (2017). Discovery of a small-molecule bromodomain-containing protein 4 (BRD4) inhibitor that induces AMP-activated protein kinase-modulated autophagy-associated cell death in breast cancer. Journal of medicinal chemistry, 60(24), 9990-10012.

Liu, Z., Wang, P., Chen, H., Wold, E. A., Tian, B., Brasier, A. R., & Zhou, J. (2017). Drug discovery targeting bromodomain-containing protein 4. Journal of medicinal chemistry, 60(11), 4533-4558.

Ask a question We look forward to hearing from you.
0 reviews or Q&As
Loading...
Have you used Mouse Anti-BRD4 (AA 530-580) Recombinant Antibody (CBYY-0806)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon $30 eGift Card
Submit a review
Loading...
For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Documents

Contact us

  • Tel: (USA)
  • (UK)
  • Fax:
  • Email:

Submit A Review

Go to
Compare